85%Confidence
0Views
FDASource
2026-04-07Date
Summary
Chiesi USA's Class II recall for CUROSURF due to sterility concerns affects a critical neonatal drug, potentially endangering vulnerable patients and inviting regulatory action. This could damage Chiesi's reputation in specialty care and result in supply constraints for hospitals.
Actionable: Track Chiesi's communication with healthcare providers regarding alternative treatments and recall resolution.
AI Confidence: 85%
Data Points
firmChiesi USA, Inc.
classificationClass II
statusOngoing
distributionNationwide within the United States
productCUROSURF (poractant alfa), 240 mg, Intratracheal Suspension, 3L Single-dose-Vial, Rx only, Chiesi USA, Inc, Cary, NC 27518, NDC 10122-510-03.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now